The latest news:

• Publication Reports Role of Dopamine Receptors in Cancer and ONC201 Response         The article they mention is at http://clincancerres.aacrjournals.org/content/early/2018/12/19/1078-0432.CCR-18-2572.long but it is not free. It shows that the DRD2 is overexpressed in many types of cancer.  Onc-201 blocks that receptor, but they also found that high levels of DRD5 make the cells resistant to the Onc-201.  So for this drug to work, we need high DRD2 and low DRD5.  That happens in most brainstem gliomas, and high grade gliomas that are in the midline of the brain - especially those in the thalamus, and in younger patients.   There are about 14 clinical trials going on for Onc201 in various cancers, including brain.  For those who do not qualify for the clinical trials, there is a compassionate use program available – contact us (the Musella Foundation)  for details 888-295-4740  

   
  




• Copay assistance program is now open!         Thanks to generous donations, we are able to reopen our copay assistance program!  We have a lookback period of 3 months from when the completed application arrives so if you are approved, and have paid for a covered treatment in the last 3 months we can reimburse you!  
  



• Optune Open House, Newton, MA         These are great get togethers for any brain tumor patient or anyone who knows a brain tumor patient!  
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants